

# RESPONSE TO VACCINATION ANTI HEPATITIS B IN ADVANCED CHRONIC KIDNEY DISEASE (CKD): COMPARING TWO DIFFERENTS VACCINES



## INTRODUCTION

It is well-known the poor response to anti Hepatitis B vaccination, in patients under Dialysis program and the improvements achieved when this is made in Pre-dialysis phase.




This case study's **OBJECTIVE** is analyze the response to this vaccination, comparing two different vaccines, ENGERIX B(DNA, adsorbed) and FENDRIX B(DNA adsorbed and adyuvanted with MPL).

## PATIENTS AND METHODS



- 115 patients were included: 73 Men and 42 Women, average age  $X:67,3 \pm 11.6$ , with CKD grade 4-5 (MDRD-4:  $15.17 \pm 5$ ) secondary to common etiologies.
- Previously HbsAg, HbcAb and HbsAb were determined and, 2 months after the treatment, HbsAb.
- Vaccination pattern was the same for everyone: 0, 1, 2 and 6 months and was repeated with no response.
  - 62 patients (Group A) were administrated by EngerixB, 40 mcg IM for each one.
  - 53 patients (Group B) Fendrix B, 20 mcg.
  - Positive response was considered, when HbsAb title was  $\geq 10$  mUI/ml.
  - Both groups were similar in terms of age, eGF and etiology.

## RESULTS

**1.- Vaccination response:** Positive response in 91 patients (79.1%): 81 patients in a first attempt and 10 more in a 2<sup>o</sup> attempt.  
- This data is similar to both groups (A 80.3%, B 79.2%).



**2.- Response by age:** Patients under 75 years old (70%), reponses by 91.2% (A 92%,B 88.5%), against patients above 75 years old, responding by 48%(A 54,B 36%). This result is significantly worse by age.



**3.- HbsAB title:** similar to both groups.

**4.- No significant statistical difference for the rest studied paramethers**

## CONCLUSIONS

- Good response after vaccination in advanced CKD patients against dialysis results made recommendable vaccination the earliest.
- We have not found results differences between vaccines used.
- Elderly, has been shown as the most important factor for vaccination.
- The advantage of more comfort for patient using Fendrix, faces with the important economical difference between both.

